Delivery Order SPE2DB25D3020-SPE2DB25FWJTW
- Not listed
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for Esbriet 801 mg tablets (90-count supply) on July 7, 2025, with an ultimate completion date of July 28, 2025. This is a competitively awarded, firm fixed-price contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Esbriet 801 mg on August 28, 2025, with completion targeted by September 19, 2025. This competitively awarded, firm fixed-price contract was issued without set-aside provisions and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed price delivery order to AmerisourceBergen Drug Corp for Esbriet (pirfenidone) 801 mg tablets in a quantity of 90 units. This award, issued on July 21, 2025, with an ultimate completion date of August 11, 2025, represents a non-competitive delivery order under AmerisourceBergen's existing federal contract vehicle. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Esbriet (pirfenidone) 801 mg tablets in a 90-count package. This competitively awarded, firm fixed price delivery order carries a ceiling value of $3,425.95 and is scheduled for completion by July 10, 2025. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside award, this delivery...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Esbriet (pirfenidone) 267 mg tablets in a quantity of 270 units. This non-set-aside, competitively awarded contract carries a firm fixed price structure with an ultimate completion date of October 8, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Esbriet (pirfenidone) 801 mg tablets in a 90-count quantity. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 13, 2025, and performance location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply contract vehicle with DLA, enabling the company...
- The Defense Logistics Agency awarded a delivery order valued at $3,425.95 to AmerisourceBergen Drug Corp for 90-count packages of Esbriet (pirfenidone) 801 mg tablets. This is a competitive, firm fixed-price delivery order with no set-aside designation, issued on August 19, 2025, with an ultimate completion date of September 10, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed price delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, a pharmaceutical product used to treat idiopathic pulmonary fibrosis. The contract, awarded on July 21, 2025, with an ultimate completion date of August 11, 2025, was competitively awarded without set-aside provisions. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $10,277.85 delivery order to AmerisourceBergen Drug Corp for Esbriet (pirfenidone) 801 mg tablets, quantity 90, with an ultimate completion date of August 20, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The pharmaceutical product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract action under...
- The Defense Logistics Agency issued a delivery order on June 16, 2025, to AmerisourceBergen Drug Corp for the supply of Esbriet (pirfenidone) 267 mg tablets in a quantity of 270 tablets, with a ceiling value of $3,425.95. This order is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 9, 2025....
- SPE2DB25D3020Indefinite Delivery Contract
- SPE2DB25D3020-SPE2DB25FWJTWDelivery Order
The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg on July 30, 2025, with an ultimate completion date of August 20, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The delivery order will be performed at the company's corporate office location in Conshohocken, PA. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The prime IDV serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, and vaccines. Esbriet (pirfenidone) is an antifibrotic medication used to treat idiopathic pulmonary fibrosis, reflecting the breadth of therapeutic domains supported through DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 7/30/25 |